Skip to main content

Table 5 Seropositivity analysis of JDM patients and HC at each study visit

From: Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study

Baseline visit  
  JDM A (n = 10) JDM B (n = 13) JDM C (n = 14) p-value JDM Total (n = 37)a HC (n = 39)a p-value
HPV 16, n (%) 1 (10.0) 6 (46.0) 3 (21.0) 0.142 10 (27.0) 2 (5.0) 0.012
HPV 18, n (%) 1 (10.0) 4 (31.0) 4 (29.0) 0.571 9 (24.0) 1 (3.0) 0.006
After the second qHPV vaccine dose  
  JDM A (n = 10) JDM B (n = 11) JDM C (n = 15) p-value JDM Total (n = 36)b HC (n = 14)c p-value
HPV 16, n (%) 10 (100) 10 (91.0) 14 (93.0) 1.000 34 (94.0) 14 (100) 1.000
HPV 18, n (%) 10 (100) 10 (91.0) 13 (87.0) 0.770 33 (92.0) 14 (100) 0.265
After the thrid qHPV vaccine dose  
  JDM A (n = 8) JDM B (n = 11) JDM C (n = 12) p-value JDM Total (n = 31)b HC (n = 31)c p-value
HPV 16, n (%) 8 (100) 11 (100) 12 (100) 31 (100) 31 (100) 1.000
HPV 18, n (%) 8 (100) 11 (100) 11 (92.0) 1.000 30 (97.0) 31 (100) 1.000
Six months after the third qHPV vaccine dose  
  JDM A (n = 5) JDM B (n = 7) JDM C (n = 5) p-value JDM Total (n = 17)b HC p-value
HPV 16, n (%) 5 (100) 6 (86.0) 5 (100) 1.000 16 (94.0) NA NA
HPV 18, n (%) 5 (100) 6 (86.0) 5 (100) 1.000 16 (94.0) NA NA
  1. JDM juvenile dermatomyositis, HC healthy controls, HPV human papillomavirus, qHPV quadrivalent HPV vaccine, NA not applicable
  2. aFive patients and two HC who had received doses of the vaccine before the study inclusion were excluded from this analysis
  3. bForty-two JDM patients completed the 3-dose vaccination schedule, however blood samples were collected only from 36 patients after the second dose, 31 after the third dose, and 17 6 months after the third dose
  4. cThirty-five HC completed the 3-dose vaccination schedule; however, blood samples were collected only from 14 HC after the second dose, and 31 after the third dose